TauroLock -Model U25.000 -Catheter Lock Solution
We have developed catheter lock solutions for patients in various contexts. TauroLock™-U25.000 provides a particularly strong prophylaxis against occlusion, as urokinase serves to break up blood clotting.
TauroLock™-U25.000 has been approved for instillation in all central-venous access systems. This lock solution reliably prevents the formation of bacterial biofilms within catheters. As a result, patients can avoid infections and maintain a high patency rate.
TauroLock™-U25.000 is based on three active ingredients:
- taurolidine
- citrate (4 %)
- urokinase (25,000 units)
Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE), while citrate works as an anticoagulant. At the same time, urokinase yields a thrombolytic effect.
Before applying TauroLock™-U25.000, dissolve the vial’s content (i.e. 25,000 IU urokinase) with 5 ml of TauroLock™. In-between treatment sessions, TauroLock™-U25.000 is instilled into the vascular access system. Please note that medical staff must check the filling volume of the respective catheter or port system.
TauroLock™-U25.000 is contraindicated:
- for patients with a known allergy to (cyclo)-taurolidine, citrate or urokinase,
- or when a patient is currently taking medication with known adverse interaction to citrate, (cyclo)-taurolidine or urokinase.
Prior to the next treatment, TauroLock™-U25.000 must be aspirated and discarded according to the institution’s policy for infectious waste disposal.
You may purchase TauroLock™-U25.000 in vials of 5 ml (single dose, 5 vials per box).
TauroLock™-U25.000 must be stored at 15 °C to 25 °C. Please note that you must not freeze TauroLock™-U25.000 under any circumstances.